The field of cardiovascular pharmacotherapy remains extremely active. The aim of this review is to summarize the recent major advances in cardiovascular pharmacotherapy, with a focus on (1) the new approved drug for treatment of heart failure with reduced ejection fraction-sacubitril/valsartan; (2) proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors; (3) the novel reversal agents for non-vitamin K oral anticoagulants (NOACs); and finally, (4) new evidence on pharmacological treatment of coronary artery disease.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00228-018-2453-1 | DOI Listing |
Publication Analysis
Top Keywords
cardiovascular pharmacotherapy
12
major advances
8
advances cardiovascular
8
pharmacotherapy field
4
field cardiovascular
4
pharmacotherapy remains
4
remains extremely
4
extremely active
4
active aim
4
aim review
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!